Sort
48,018 grants matching “immunotherapy”
Immunobiology of Myeloid and Lymphoid Cells
$399,553Charles L Sentman · Dartmouth College · T32 · FY2012 · AI
Development of Programmable mRNA Circuits for Melanoma Immunotherapy
$399,508Ryan Sowell · Strand Therapeutics Inc · R43 · FY2021 · CA
An innovative telomerase-targeted, circulating tumor cell assay for monitoring NSCLC treated with radiation and immunotherapy
$399,499Deeksha Saxena · Liquid Biodx Llc · R43 · FY2023 · CA
SOUTHWEST ONCOLOGY GROUP
$399,443Swedish Medical Center, First Hill · U10 · FY2002 · CA
Novel Anti-CCR8 VHH for the Treatment of NSCLC
$399,424Mauro Mileni · Abilita Bio, Inc. · R43 · FY2023 · CA
ST8Sia6 expression on tumors inhibits the immune response
$399,403Virginia Smith Shapiro · Mayo Clinic Rochester · R01 · FY2021 · CA
The role of the CD58:CD2 axis in cancer immune evasion and resistance to immunotherapy
$399,379Benjamin Izar · Columbia University Health Sciences · R01 · FY2023 · CA
A Uniquely Scalable Approach to Single Cell Sequencing for the Development of Next Generation Cell Therapies
$399,369Philipp Stefan Spuhler · Sansimeon, Inc · R43 · FY2024 · HG
EFFECTOR AND MEMORY ANTIMALARIA CD8+ CELL RESPONSES
$399,356New York University School Of Medicine · R01 · FY2002 · AI
Development of Immunostimulatory Virotherapy Without Neurotoxicity for the Treatment of Brain Malignancies
$399,335Matthew Stremlau · Implicyte, Inc. · R43 · FY2021 · CA
Off-the-shelf engineered NK cells to treat glioblastoma
$399,314Joe Trebley · Monon Bioventures, Llc · R43 · FY2022 · CA
Regulation of PD-L1/PD-1 immune checkpoints by cis-interactions
$399,303Enfu Hui · University Of California, San Diego · R37 · FY2022 · CA
Phase II Trial of Arimoclomol in IBM
$399,300Mazen Dimachkie · University Of Kansas Medical Center · R01 · FY2019 · FD
Targeted Delivery of Tumor Antigen esaRNA to the Spleen for Cancer Immunotherapy
$399,300Jasdave Chahal · Tiba Biotech, Llc · R43 · FY2025 · CA
Microfluidic vortex shedding: a low-cost, high efficiency method for genetic modification to support cell engineering for cell-based immunotherapies
$399,299Justin Jarrell · Indee, Inc · N43 · FY2020 · CA
Augmenting focused ultrasound-mediated drug delivery to brain tumors with vascular normalization
$399,294Richard J Price · University Of Virginia · R21 · FY2024 · CA
Project 3: Systematic characterization of factors controlling breast cancer progression and resistance
$399,288Michael C Bassik · Stanford University · U54 · FY2022 · CA
Tumor-activatable Interleukin-2 Superkine Nanoparticle Therapy
$399,271Jinming Gao · Ut Southwestern Medical Center · R01 · FY2025 · CA
Tumor-activatable Interleukin-2 Superkine Nanoparticle Therapy
$399,271Jinming Gao · Ut Southwestern Medical Center · R01 · FY2024 · CA
An allogeneic gamma/delta armored Dual-Targeting CAR with Split Costimulatory Domains to Target Epithelial Ovarian Carcinoma
$399,256Samuel Hickenlooper · Luminary Therapeutics, Inc. · R43 · FY2024 · CA
Inhibitory Pathways Underlying Viral Persistance in vivo
$399,245Elina I Zuniga · University Of California, San Diego · R01 · FY2011 · AI
Role of Ly6K in TGF-beta and immune escape pathways of triple negative breast cancer
$399,241Geeta Upadhyay · Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2021 · CA
Strategies to Enhance Adoptive Transfer T Cell Clones
$399,222Fred Hutchinson Cancer Research Center · R01 · FY2005 · CA
Shifting the immune infiltrates in osteosarcoma lung metastases with locally targeted CSF-1Ris for combination therapies
$399,187Sandro R. P. Da Rocha · Virginia Commonwealth University · R21 · FY2021 · CA
Modeling Marginal Zone Lymphomagenesis
$399,187Victor Yazbeck · Virginia Commonwealth University · R21 · FY2024 · CA